(2005024633)

22 APR 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037203 A3

(51) International Patent Classification[7]: A61K 9/22

(21) International Application Number:
PCT/US2003/033931

(22) International Filing Date: 24 October 2003 (24.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/421,258	24 October 2002 (24.10.2002)	US
60/507,312	29 September 2003 (29.09.2003)	US
60/512,035	17 October 2003 (17.10.2003)	US

(71) Applicant *(for all designated States except US)*: **ENOS PHARMACEUTICALS, INC.** [—/US]; One Canal Park, Cambridge, MA 02141 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **RON, Eyal, S.** [US/US]; 7 Coach Road, Lexington, MA 02420-1101 (US).

(74) Agents: **SMITH, DeAnn, F.** et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
16 September 2004

(15) Information about Correction:
Previous Correction:
see PCT Gazette No. 30/2004 of 22 July 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162



ACTION

WO 2004/037203 A3

(54) Title: SUSTAINED RELEASE L-ARGININE FORMULATIONS AND METHODS OF MANUFACTURE AND USE

(57) Abstract: The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such to as L-arginine, may be used to treat or prevent cerebrovascular and/or cardiovascular diseases or disorders.